Table of Contents

company-logo

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Praxis Precision Medicines Dividend Announcement

• Praxis Precision Medicines does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Praxis Precision Medicines dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Praxis Precision Medicines Dividend History

Praxis Precision Medicines Dividend Yield

Praxis Precision Medicines current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Praxis Precision Medicines stock? Use our calculator to estimate your expected dividend yield:

Praxis Precision Medicines Financial Ratios

P/E ratio-10.61
PEG ratio-0.11
P/B ratio4.19
ROE-54.86%
Payout ratio0.00%
Current ratio10.96
Quick ratio10.96
Cash Ratio5.13

Praxis Precision Medicines Dividend FAQ

Does Praxis Precision Medicines stock pay dividends?
Praxis Precision Medicines does not currently pay dividends to its shareholders.
Has Praxis Precision Medicines ever paid a dividend?
No, Praxis Precision Medicines has no a history of paying dividends to its shareholders. Praxis Precision Medicines is not known for its dividend payments.
Why doesn't Praxis Precision Medicines pay dividends?
There are several potential reasons why Praxis Precision Medicines would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Praxis Precision Medicines ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Praxis Precision Medicines has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Praxis Precision Medicines a dividend aristocrat?
Praxis Precision Medicines is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Praxis Precision Medicines a dividend king?
Praxis Precision Medicines is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Praxis Precision Medicines a dividend stock?
No, Praxis Precision Medicines is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Praxis Precision Medicines stocks?
To buy Praxis Precision Medicines you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Praxis Precision Medicines stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.